[HTML][HTML] Lower-dose prescribing: minimizing “side effects” of pharmaceuticals on society and the environment
CG Daughton, IS Ruhoy - Science of the total Environment, 2013 - Elsevier
The prescribed use of pharmaceuticals can result in unintended, unwelcomed, and
potentially adverse consequences for the environment and for those not initially targeted for …
potentially adverse consequences for the environment and for those not initially targeted for …
[HTML][HTML] Lower-dose prescriptions in the post-marketing situation and the influencing factors thereon
A Ogata, M Kaneko, M Narukawa - Plos one, 2019 - journals.plos.org
The dosage of pharmaceuticals is determined through the process of clinical development
and approval review based on clinical trial results; however, the information obtained from …
and approval review based on clinical trial results; however, the information obtained from …
臨床試験における安全性を理由とした治験薬の投与中止・減量と市販後の低用量処方の関係
緒方映子， 成川衛 - YAKUGAKU ZASSHI, 2021 - jstage.jst.go.jp
抄録 Dosage of pharmaceuticals is determined and approved based on pivotal clinical trial
results in Phase 3. However, in the post-marketing setting, it is often adjusted according to …
results in Phase 3. However, in the post-marketing setting, it is often adjusted according to …
[PDF][PDF] 臨床開発及び臨床使用実態からみた用量最適化に関する研究
緒方映子， オガタアキコ - kitasato.repo.nii.ac.jp
[背景・目的] 医薬品を有効かつ安全に使用するにあたり, 投与量の決定は重要な事項のひとつで
ある. 一般に医薬品の推奨用量は臨床開発及び承認審査の過程において臨床試験成績に基づき …
ある. 一般に医薬品の推奨用量は臨床開発及び承認審査の過程において臨床試験成績に基づき …
[CITATION][C] Research on dose optimization from the aspect of clinical development and real-world use
A Ogata